Drug development is a costly, time-intensive and high-risk endeavour, with only two to three approvals for novel therapeutics in new drug classes per year eventually making it to market. New strategies are required to identify promising new drug candidates early on and, likewise, to terminate those candidates that are unlikely to be successful, thus allowing a more rapid and efficient move to pivotal trials.
Molecular imaging attempts to characterize and quantify biological processes at the cellular and subcellular level in intact living subjects. It exploits specific molecular probes and intrinsic tissue characteristics as the source of image contrast, providing the potential for understanding of integrative biology, earlier detection and characterization of disease, and evaluation of treatment.
As most molecular imaging techniques are routine in clinical radiology departments and have counterparts in the experimental research setting, it is possible to design preclinical experiments that not only predict clinical imaging observations but also provide a mechanistic understanding of the observed biological response.
Molecular imaging has the potential to have a significant impact on different phases of drug development, including target expression, compound screening and optimization, as well as Phases I to III clinical studies. Examples are detailed in the text of the article.
The option of an exploratory IND (eIND) initiated by the US Food and Drug Administration enables first-in-human molecular imaging studies to be performed with reduced preclinical support as compared to that required for a full IND.
Consortia such as the Alzheimer's Disease Neuroimaging Initiative, the American College of Radiology Imaging Network and the High-Risk Plaque Initiative seek to correlate a number of imaging biomarkers with the clinical manifestations of diseases and, if successful, will greatly increase the inclusion of these imaging techniques in exploratory clinical development of novel therapeutics.
Molecular imaging can allow the non-invasive assessment of biological and biochemical processes in living subjects. Such technologies therefore have the potential to enhance our understanding of disease and drug activity during preclinical and clinical drug development, which could aid decisions to select candidates that seem most likely to be successful or to halt the development of drugs that seem likely to ultimately fail. Here, with an emphasis on oncology, we review the applications of molecular imaging in drug development, highlighting successes and identifying key challenges that need to be addressed for successful integration of molecular imaging into the drug development process.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003). Gives a cost estimation for development of future drugs.
Lindsay, M. A. Target discovery. Nature Rev. Drug Discov. 2, 831–838 (2003).
Zambrowicz, B. P. & Sands, A. T. Knockouts model the 100 best-selling drugs — will they model the next 100? Nature Rev. Drug Discov. 2, 38–51 (2003).
DiMasi, J. A., Hansen, R. W., Grabowski, H. G. & Lasagna, L. Cost of innovation in the pharmaceutical industry. J. Health Econ. 10, 107–142 (1991).
Rudin, M. Imaging in Drug Discovery and Early Clinical Trials (Progress in Drug Research) Vol. 62 Foreword (Birkhauser, Switzerland, 2005).
Massoud, T. F. & Gambhir, S. S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17, 545–580 (2003). A detailed review on molecular imaging strategies.
Sosnovik, D. & Weissleder, R. Magnetic resonance and fluorescence based molecular imaging technologies. Prog. Drug Res. 62, 83–115 (2005).
Hildebrandt, I. J. & Gambhir, S. S. Molecular imaging applications for immunology. Clin. Immunol. 111, 210–224 (2004).
Min, J. J. & Gambhir, S. S. Gene therapy progress and prospects: noninvasive imaging of gene therapy in living subjects. Gene Ther. 11, 115–125 (2004).
Penuelas, I., Haberkorn, U., Yaghoubi, S. & Gambhir, S. S. Gene therapy imaging in patients for oncological applications. Eur. J. Nucl. Med. Mol. Imaging 32 (Suppl. 2), 384–403 (2005).
Ray, P. et al. Monitoring gene therapy with reporter gene imaging. Semin. Nucl. Med. 31, 312–320 (2001).
Schipper, M., Gambhir, S. S. in Diagnostic Nuclear Medicine (ed. Schiepers, C.) 313–342 (Springer, Berlin, Heidelberg, 2006).
Kung, A. L. et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6, 33–43 (2004).
Wang, W. & El-Deiry, W. S. Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol. Ther. 2, 196–202 (2003).
Wang, W. et al. Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol. Ther. 4, 893–898 (2005).
Luker, K. E. & Piwnica-Worms, D. Optimizing luciferase protein fragment complementation for bioluminescent imaging of protein-protein interactions in live cells and animals. Methods Enzymol. 385, 349–360 (2004).
Massoud, T. F., Paulmurugan, R., De, A., Ray, P. & Gambhir, S. S. Reporter gene imaging of protein–protein interactions in living subjects. Curr. Opin. Biotechnol. 18, 31–37 (2007).
Massoud, T. F., Paulmurugan, R. & Gambhir, S. S. Molecular imaging of homodimeric protein–protein interactions in living subjects. FASEB J. 18, 1105–1107 (2004).
Paulmurugan, R. & Gambhir, S. S. Novel fusion protein approach for efficient high-throughput screening of small molecule-mediating protein–protein interactions in cells and living animals. Cancer Res. 65, 7413–7420 (2005).
Paulmurugan, R. & Gambhir, S. S. An intramolecular folding sensor for imaging estrogen receptor–ligand interactions. Proc. Natl Acad. Sci. USA 103, 15883–15888 (2006).
Paulmurugan, R. & Gambhir, S. S. Combinatorial library screening for developing an improved split-firefly luciferase fragment-assisted complementation system for studying protein–protein interactions. Anal. Chem. 79, 2346–2353 (2007).
Paulmurugan, R., Massoud, T. F., Huang, J. & Gambhir, S. S. Molecular imaging of drug-modulated protein–protein interactions in living subjects. Cancer Res. 64, 2113–2119 (2004).
Paulmurugan, R., Ray, P., De, A., Chan, C. T. & Gambhir, S. S. in Protein–Protein Interactions: A Molecular Cloning Manual (eds Golemis, E. & Adams, P. D.) 695–713 (Cold Spring Harbor Laboratory Press, New York, 2005).
Paulmurugan, R., Ray, P., De, A., Chan, C. T. & Gambhir, S. S. Imaging protein–protein interactions in living subjects. Trends Analyt. Chem. 24, 446–458 (2005).
Paulmurugan, R., Umezawa, Y. & Gambhir, S. S. Noninvasive imaging of protein–protein interactions in living subjects by using reporter protein complementation and reconstitution strategies. Proc. Natl Acad. Sci. USA 99, 15608–15613 (2002).
Luker, G. D., Sharma, V. & Piwnica-Worms, D. Visualizing protein–protein interactions in living animals. Methods 29, 110–122 (2003).
Villalobos, V., Naik, S. & Piwnica-Worms, D. Current state of imaging protein–protein interactions in vivo with genetically encoded reporters. Annu. Rev. Biomed. Eng. 9, 321–349 (2007).
Chan, C. T. et al. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Res. 68, 216–226 (2008). A study on the use of molecular imaging for screening drug efficacy.
Forster, T. Zwischenmolekulare energiewanderung und fluoreszenz. Ann. Phys. 2, 54–75 (1948) (in German).
De, A. & Gambhir, S. S. Noninvasive imaging of protein–protein interactions from live cells and living subjects using bioluminescence resonance energy transfer. FASEB J. 19, 2017–2019 (2005).
De, A., Loening, A. M. & Gambhir, S. S. An improved bioluminescence resonance energy transfer strategy for imaging intracellular events in single cells and living subjects. Cancer Res. 67, 7175–7183 (2007).
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. Nature Rev. Cancer 2, 683–693 (2002).
Warburg, O., Posener, K. & Negelein, E. Ueber den stoffwechsel der tumoren. Biochemische Zeitschrift 152, 319–344 (1924) (in German).
Gambhir, S. S. et al. A tabulated summary of the FDG PET literature. J. Nucl. Med. 42, 1S–93S (2001).
Czernin, J. & Phelps, M. E. Positron emission tomography scanning: current and future applications. Annu. Rev. Med. 53, 89–112 (2002).
Czernin, J., Allen-Auerbach, M. & Schelbert, H. R. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J. Nucl. Med. 48 (Suppl. 1), 78–88 (2007).
Van den Abbeele, A. D. & Badawi, R. D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur. J. Cancer 38 (Suppl. 5), 60–65 (2002). A study on the use of FDG–PET in humans for early assessment of therapeutic effects of the drug imatinib mesylate.
Bombardieri, E. The added value of metabolic imaging with FDG–PET in oesophageal cancer: prognostic role and prediction of response to treatment. Eur. J. Nucl. Med. Mol. Imaging 33, 753–758 (2006).
Kramer, H., Post, W. J., Pruim, J. & Groen, H. J. The prognostic value of positron emission tomography in non-small cell lung cancer: analysis of 266 cases. Lung Cancer 52, 213–217 (2006).
Hawkins, D. S. et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J. Clin. Oncol. 23, 8828–8834 (2005).
Hoekstra, C. J. et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 8362–8370 (2005).
Xue, F. et al. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol. Oncol. 101, 147–151 (2006).
Kieninger, A. N., Welsh, R., Bendick, P. J., Zelenock, G. & Chmielewski, G. W. Positron-emission tomography as a prognostic tool for early-stage lung cancer. Am. J. Surg. 191, 433–436 (2006).
Svoboda, J. et al. Prognostic value of FDG–PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 38, 211–216 (2006).
Eschmann, S. M. et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 34, 463–471 (2007).
Hutchings, M. et al. FDG–PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107, 52–59 (2006).
Kostakoglu, L. et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J. Nucl. Med. 43, 1018–1027 (2002).
Levine, E. A. et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG–PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann. Surg. 243, 472–478 (2006).
Mikhaeel, N. G., Hutchings, M., Fields, P. A., O'Doherty, M. J. & Timothy, A. R. FDG–PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann. Oncol. 16, 1514–1523 (2005).
Spaepen, K. et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann. Oncol. 13, 1356–1363 (2002).
Veit, P. et al. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur. Radiol. 16, 80–87 (2006).
Ware, R. E. et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck 26, 1008–1017 (2004).
Dehdashti, F. et al. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur. J. Nucl. Med. 26, 51–56 (1999).
Prenen, H. et al. Imatinib mesylate inhibits glucose uptake in gastrointestinal stromal tumor cells by downregulation of the glucose transporters recruitment to the plasma membrane. Am. J. Biochem. Biotechnol. 1, 95–102 (2005).
Isselbacher, K. J. Sugar and amino acid transport by cells in culture — differences between normal and malignant cells. N. Engl. J. Med. 286, 929–933 (1972).
Jager, P. L. et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J. Nucl. Med. 42, 432–445 (2001).
Oka, S. et al. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J. Nucl. Med. 48, 46–55 (2007).
Schuster, D. M. et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J. Nucl. Med. 48, 56–63 (2007).
Katz-Brull, R., Seger, D., Rivenson-Segal, D., Rushkin, E. & Degani, H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 62, 1966–1970 (2002).
Liu, D. et al. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br. J. Cancer 87, 783–789 (2002).
Kelloff, G. J. et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin. Cancer Res. 11, 7967–7985 (2005).
Tseng, J. R. et al. Reproducibility of 3′-deoxy-3′-18F-fluorothymidine microPET studies in tumor xenografts in mice. J. Nucl. Med. 46, 1851–1857 (2005).
Leyton, J. et al. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 65, 4202–4210 (2005).
Buck, A. K. et al. 3-deoxy-3-[18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 62, 3331–3334 (2002).
Vesselle, H. et al. In vivo validation of 3′deoxy-3′-[18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans: correlation of [18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin. Cancer Res. 8, 3315–3323 (2002).
Perumal, M. et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res. 66, 8558–8564 (2006).
Blasberg, R. G. et al. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res. 60, 624–635 (2000).
Sun, H. et al. Imaging DNA synthesis in vivo with 18F-FMAU and PET. J. Nucl. Med. 46, 292–296 (2005).
Kenny, L. M., Aboagye, E. O. & Price, P. M. Positron emission tomography imaging of cell proliferation in oncology. Clin. Oncol. (R. Coll. Radiol.) 16, 176–185 (2004).
Mankoff, D. A., Shields, A. F. & Krohn, K. A. PET imaging of cellular proliferation. Radiol. Clin. North Am. 43, 153–167 (2005).
Hajra, K. M. & Liu, J. R. Apoptosome dysfunction in human cancer. Apoptosis 9, 691–704 (2004).
Hersey, P. & Zhang, X. D. Overcoming resistance of cancer cells to apoptosis. J. Cell Physiol. 196, 9–18 (2003).
Blankenberg, F. G. et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl Acad. Sci. USA 95, 6349–6354 (1998).
Blankenberg, F. G. et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J. Nucl. Med. 40, 184–191 (1999).
Glaser, M. et al. Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl. Radiat. Isot. 58, 55–62 (2003).
Grierson, J. R. et al. Production of [F-18]fluoroannexin for imaging apoptosis with PET. Bioconjug. Chem. 15, 373–379 (2004).
Belhocine, T., Steinmetz, N., Green, A. & Rigo, P. In vivo imaging of chemotherapy-induced apoptosis in human cancers. Ann. NY Acad. Sci. 1010, 525–529 (2003).
Belhocine, T. et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res. 8, 2766–2774 (2002).
Boersma, H. H. et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. J. Nucl. Med. 46, 2035–2050 (2005).
Corsten, M. F., Hofstra, L., Narula, J. & Reutelingsperger, C. P. Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance. Cancer Res. 66, 1255–1260 (2006).
Blankenberg, F. G., Backer, M. V., Levashova, Z., Patel, V. & Backer, J. M. In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur. J. Nucl. Med. Mol. Imaging 33, 841–848 (2006).
Haubner, R. αvβ3-integrin imaging: a new approach to characterise angiogenesis? Eur. J. Nucl. Med. Mol. Imaging 33 (Suppl. 13), 54–63 (2006).
Haubner, R. et al. Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med. 40, 1061–1071 (1999).
Chen, X., Conti, P. S. & Moats, R. A. In vivo near-infrared fluorescence imaging of integrin αvβ3 in brain tumor xenografts. Cancer Res. 64, 8009–8014 (2004).
Haubner, R. et al. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61, 1781–1785 (2001).
Janssen, M. L. et al. Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model. Cancer Res. 62, 6146–6151 (2002).
van Hagen, P. M. et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int. J. Cancer 90, 186–198 (2000).
Beer, A. J. et al. Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J. Nucl. Med. 49, 22–29 (2008). A study on translation of angiogenesis imaging with PET to humans.
Beer, A. J. et al. Patterns of αvβ3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J. Nucl. Med. 49, 255–259 (2008).
Haubner, R. et al. Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2, e70 (2005).
Zhang, X. et al. Quantitative pet imaging of tumor integrin αvβ3 expression with 18F-FRGD2. J. Nucl. Med. 47, 113–121 (2006).
Cai, W. et al. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin αvβ3 . Cancer Res. 66, 9673–9681 (2006).
Cai, W. et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 6, 669–676 (2006).
Ellegala, D. B. et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to αvβ3 . Circulation 108, 336–341 (2003). A proof-of-principle study on ultrasonic tumour angiogenesis imaging using microbubbles targeted to α v β 3 integrin.
Korpanty, G., Carbon, J. G., Grayburn, P. A., Fleming, J. B. & Brekken, R. A. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin. Cancer Res. 13, 323–330 (2007).
Willmann, J. K. et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 246, 508–518 (2008).
Willmann, J. K. et al. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic MicroPET imaging in mice. Radiology (in the press).
Willmann, J. K. et al. Dual-targeted contrast agent for ultrasonic assessment of tumor angiogenesis in vivo. Radiology (in the press).
Bremer, C., Bredow, S., Mahmood, U., Weissleder, R. & Tung, C. H. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 221, 523–529 (2001).
Cai, W., Rao, J., Gambhir, S. S. & Chen, X. How molecular imaging is speeding up antiangiogenic drug development. Mol. Cancer Ther. 5, 2624–2633 (2006).
Rehman, S. & Jayson, G. C. Molecular imaging of antiangiogenic agents. Oncologist 10, 92–103 (2005).
Rasey, J. S. et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 36, 417–428 (1996).
Koh, W. J. et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 33, 391–398 (1995).
Koh, W. J. et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys. 22, 199–212 (1992).
Dehdashti, F. et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response — a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 55, 1233–1238 (2003).
Dehdashti, F. et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur. J. Nucl. Med. Mol. Imaging 30, 844–850 (2003).
Solomon, B. et al. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol. Cancer Ther. 4, 1417–1422 (2005).
Foo, S. S., Abbott, D. F., Lawrentschuk, N. & Scott, A. M. Functional imaging of intratumoral hypoxia. Mol. Imaging Biol. 6, 291–305 (2004).
Rajendran, J. G. & Krohn, K. A. Imaging hypoxia and angiogenesis in tumors. Radiol. Clin. North Am. 43, 169–187 (2005).
Dimasi, J. A. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69, 297–307 (2001).
Rudin, M. & Weissleder, R. Molecular imaging in drug discovery and development. Nature Rev. Drug Discov. 2, 123–131 (2003).
Fischman, A. J., Alpert, N. M. & Rubin, R. H. Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action. Clin. Pharmacokinet. 41, 581–602 (2002). A review on the use of imaging for assessing of drug pharmacokinetics.
Berridge, M. S. & Heald, D. L. In vivo characterization of inhaled pharmaceuticals using quantitative positron emission tomography. J. Clin. Pharmacol. (Suppl.), 25S–29S (1999).
Farde, L. et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49, 538–544 (1992).
Farde, L., Wiesel, F. A., Nordstrom, A. L. & Sedvall, G. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl.) 99 (Suppl.), S28–S31 (1989).
Bench, C. J. et al. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-001) determined by positron emission tomography. Psychopharmacology (Berl.) 124, 141–147 (1996).
Hode, Y. et al. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian). Psychopharmacology (Berl.) 180, 377–384 (2005).
Farde, L. The advantage of using positron emission tomography in drug research. Trends Neurosci. 19, 211–214 (1996).
Wilding, I. R. & Bell, J. A. Improved early clinical development through human microdosing studies. Drug Discov. Today 10, 890–894 (2005).
Saleem, A. et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J. Clin. Oncol. 19, 1421–1429 (2001).
Saleem, A. et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res. 63, 2409–2415 (2003).
Saleem, A., Charnley, N. & Price, P. Clinical molecular imaging with positron emission tomography. Eur. J. Cancer 42, 1720–1727 (2006).
Garner, R. C. Less is more: the human microdosing concept. Drug Discov. Today 10, 449–451 (2005).
Gambhir, S. S. in PET: Molecular Imaging and Its Biological Applications (ed. Phelps, M. E.) 125–216 (Springer, New York, 2004).
Lesko, L. J. & Atkinson, A. J. Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41, 347–366 (2001).
Richter, W. S. Imaging biomarkers as surrogate endpoints for drug development. Eur. J. Nucl. Med. Mol. Imaging 33, 6–10 (2006).
Smith, J. J., Sorensen, A. G. & Thrall, J. H. Biomarkers in imaging: realizing radiology's future. Radiology 227, 633–638 (2003). A useful review on imaging biomarkers.
Pien, H. H., Fischman, A. J., Thrall, J. H. & Sorensen, A. G. Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov. Today 10, 259–266 (2005).
Wang, Y. X. Medical imaging in pharmaceutical clinical trials: what radiologists should know. Clin. Radiol. 60, 1051–1057 (2005).
Beer, A. J. et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J. Nucl. Med. 46, 1333–1341 (2005).
Weber, W. A. Positron emission tomography as an imaging biomarker. J. Clin. Oncol. 24, 3282–3292 (2006).
Katz, R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1, 189–195 (2004).
Jung, J. C. & Schnitzer, M. J. Multiphoton endoscopy. Opt. Lett. 28, 902–904 (2003).
Rudin, M., Rausch, M. & Stoeckli, M. Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods. Mol. Imaging Biol. 7, 5–13 (2005).
Schmidt, M. E. The future of imaging in drug discovery. J. Clin. Pharmacol. (Suppl), 45S–50S (1999).
Dimasi, J. A. New drug development in the United States from 1963 to 1999. Clin. Pharmacol. Ther. 69, 286–296 (2001).
Ginos, J. Z. et al. [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J. Nucl. Med. 28, 1844–1852 (1987).
Kissel, J. et al. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res. 57, 3415–3423 (1997).
Inoue, T. et al. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother. Radiopharm. 11, 235–245 (1996).
Jayson, G. C. et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J. Natl Cancer Inst. 94, 1484–1493 (2002).
Su, H. et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 12, 5659–5667 (2006).
Mankoff, D. A. et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J. Nucl. Med. 44, 1806–1814 (2003).
Anderson, H. L. et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. 21, 2823–2830 (2003).
Jacobs, A. et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358, 727–729 (2001).
Kim, Y. R. et al. Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor. Cancer Res. 65, 9253–9260 (2005).
Barentsz, J. O. et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207, 791–797 (1998).
Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 21, 3955–3964 (2003).
Robinson, S. P. et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br. J. Cancer 88, 1592–1597 (2003).
Stevenson, J. P. et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 21, 4428–4438 (2003).
Thomas, J. P. et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 21, 223–231 (2003).
Galbraith, S. M. et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 21, 2831–2842 (2003).
Wolf, W., Waluch, V. & Presant, C. A. Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed. 11, 380–387 (1998).
Blackstock, A. W. et al. Tumor uptake and elimination of 2′, 2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin. Cancer Res. 7, 3263–3268 (2001).
Rodrigues, L. M. et al. In vivo detection of ifosfamide by 31P-MRS in rat tumours: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas. Br. J. Cancer 75, 62–68 (1997).
Abdollahi, A. et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 63, 8890–8898 (2003).
Goertz, D. E., Yu, J. L., Kerbel, R. S., Burns, P. N. & Foster, F. S. High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res. 62, 6371–6375 (2002).
Iordanescu, I., Becker, C., Zetter, B., Dunning, P. & Taylor, G. A. Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors. Radiology 222, 460–467 (2002).
Franco, M. et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 66, 3639–3648 (2006).
Bertolotto, M. et al. Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results. Invest. Radiol. 41, 15–21 (2006).
Hsu, C. et al. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. Radiology 235, 509–516 (2005).
Niermann, K. J. et al. Sonographic depiction of changes of tumor vascularity in response to various therapies. Ultrasound Q. 21, 61–67; quiz 149, 153–154 (2005).
Gee, M. S. et al. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res. 61, 2974–2982 (2001).
Unger, E. C., McCreery, T. P., Sweitzer, R. H., Caldwell, V. E. & Wu, Y. Acoustically active lipospheres containing paclitaxel: a new therapeutic ultrasound contrast agent. Invest. Radiol. 33, 886–892 (1998).
Krix, M. et al. Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography. Cancer Res. 63, 8264–8270 (2003).
Shah, K., Tang, Y., Breakefield, X. & Weissleder, R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 22, 6865–6872 (2003).
Bremer, C., Tung, C. H. & Weissleder, R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nature Med. 7, 743–748 (2001). A study on optical imaging using an activatable reporter probe.
Rehemtulla, A. et al. Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol. Imaging 1, 43–55 (2002).
Laxman, B. et al. Noninvasive real-time imaging of apoptosis. Proc. Natl Acad. Sci. USA 99, 16551–16555 (2002).
Ntziachristos, V. et al. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc. Natl Acad. Sci. USA 101, 12294–12299 (2004).
Montet, X., Ntziachristos, V., Grimm, J. & Weissleder, R. Tomographic fluorescence mapping of tumor targets. Cancer Res. 65, 6330–6336 (2005).
Wu, K. D. et al. Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc. Natl Acad. Sci. USA 102, 10640–10645 (2005).
Lamfers, M. L. et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol. Ther. 14, 779–788 (2006).
We would like to acknowledge the support of the Swiss Foundation of Medical-Biological Grants (J.K.W.), the Novartis Research Foundation (J.K.W.), the Swiss Society of Radiology (J.K.W.), as well as the support of NIH grants ICMIC CA114747 P50 (S.S.G.), CCNE U54 CA 119367 (S.S.G.), R01 CA082214 (S.S.G.), R01 HL078632 (S.S.G.), Doris Duke Foundation (S.S.G.), and the Canary Foundation (S.S.G.).
S.S.G. is on the advisory board for Centella, Chiron, CTI/PetMet Pharmaceutical Inc., Endra, Enlight, Genetech, General Electric, GlaxoSmithKline, Henry Ford Health Systems, Lumen Therapeutics, MediGene Inc., Philips Medical Systems, Plexera, Varian Medical Inc., VisualSonics. He has served as a consultant for MediGene Inc., Millennium, Philips Medical Systems and Spectrum Dynamics. He has received grants from Alza, Bayer Schering, the Department of Energy, General Electric. He has had industrial research collaboration with GlaxoSmithKline, Nova R&D, Pfizer, RMD Inc. He has stocks with Endra, Enlight, Pfizer, Spectrum Dynamics, VisualSonics, and received honorarium from Siemens. N.V.B. is affiliated (employee) with Genentech. This manuscript refers to some Genentech products. L.M.D. is an employee of Bayer Schering Pharma.
- Investigational new drug application
Before initiating any clinical trials of a new drug in humans in the United States, a drug sponsor must submit an investigational new drug application (IND) to the US FDA. The IND contains three broad categories of information: data from animal pharmacology and toxicology studies, manufacturing information, and clinical protocols and investigator information.
- Tumour xenograft
Tumour specimens can be grown in immunocompromised rodents to provide tumour models with many of the complexities of human tumours.
The luciferase assay is a method to detect the presence of ATP based on the ability of the firefly enzyme luciferase to catalyse a reaction between its substrate luciferin and ATP, releasing the two terminal phosphate groups of ATP. Luciferin becomes excited during the process and, on return to its basal state, releases energy in the form of light.
- Metabolic flare
Metabolic flare corresponds to an increase of radiotracer uptake (for example, FDG) in tissue (for example, in a tumour) following radiotherapy, hormonal therapy or chemotherapy. Possible causes for this phenomenon include post-therapeutic inflammatory reactions, increased energy utilization related to induction of apoptosis, or partial agonistic effects of hormonal therapy (for example, during anti-oestrogen therapy in breast cancer).
- Bio-isosteric substitution
The substitution by a radiolabel of similar size, electronic configuration and lipophilicity for a portion of the parent drug molecule.
The steric and electronic features of a ligand that are necessary to ensure optimal interactions with a biological target structure and to trigger (or to block) its biological response.
- Chelating agent
A molecule that has the capacity of tight metal binding (complexation).
- Clinical end point
A clinical end point assesses how a patient feels, functions or survives.
About this article
Cite this article
Willmann, J., van Bruggen, N., Dinkelborg, L. et al. Molecular imaging in drug development. Nat Rev Drug Discov 7, 591–607 (2008). https://doi.org/10.1038/nrd2290
Chemistry – A European Journal (2021)
Translational Oncology (2021)
Acta Pharmaceutica Sinica B (2021)
Nuclear Medicine and Biology (2021)
Trends in Molecular Medicine (2021)